Q1 FY27 results: subsidiary going concern flag, board re-appoints director
HEALTHX · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty Microcap 250 and 1.2 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved Q1 FY27 unaudited results (standalone and consolidated). Standalone: revenue Rs 8.00 lakhs, net loss Rs 51.43 lakhs. Consolidated: revenue Rs 44,684.98 lakhs, PAT Rs 198.67 lakhs (down sharply from Rs 2,659.27 lakhs in Q1 FY26), with exceptional items of Rs 96.05 lakhs. Auditor flagged going concern uncertainty for step-down subsidiary Genu Path Labs, whose net worth has fully eroded. Board also approved re-appointment of Mrs. Anjana Dikshit as Independent Director for a second 5-year term starting Nov 10, 2026, subject to shareholder approval. A composite scheme of arrangement and amalgamation is pending approvals.
Weak standalone with losses; consolidated profits fell sharply. Going concern flag on subsidiary is a red flag, though parent's position looks stable for now.